4 completed, 2 active not recruiting, 1 terminated, 1 unknown. 8 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 4, Active not recruiting 2, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Pharming Technologies B.V.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pediatric Patients Aged 1 to 6 Years With APDS Leniolisib - APDS | Phase 3 | Active not recruiting | Pharming Technologies B.V. | 16 | 2023-08-30 | 2026-06-15 |
| An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS Leniolisib - APDS Gene Mutation | Phase 3 | Unknown | Pharming Technologies B.V. | 3 | 2023-08-03 | 2024-02-08 |
| Pediatric Patients Aged 4 to 11 Years With APDS Leniolisib - APDS | Phase 3 | Active not recruiting | Pharming Technologies B.V. | 15 | 2023-02-01 | 2026-05-06 |
| Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI CDZ173 - Activated PI3Kdelta Syndrome (APDS); PASLI Disease | Phase 2 / Phase 3 | Terminated | Pharming Technologies B.V. | 37 | 2016-09-08 | 2026-03-30 |
| Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks rhC1INH, Placebo (Saline) - Hereditary Angioedema | Phase 3 | Completed | Pharming Technologies B.V. | 75 | 2011-01-01 | 2015-08-07 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Recombinant Human C1 Inhibitor, placebo - Hereditary Angioedema, Angioneurotic Edema | Phase 2 / Phase 3 | Completed | Pharming Technologies B.V. | 77 | 2005-07-01 | 2013-02-22 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema recombinant human C1 inhibitor, Placebo - Hereditary Angioedema, Angioneurotic Edema | Phase 3 | Completed | Pharming Technologies B.V. | 75 | 2004-06-01 | 2012-10-02 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema i.v. recombinant human C1 inhibitor - Genetic Disorders | Phase 2 / Phase 3 | Completed | Pharming Technologies B.V. | 14 | 2004-04-01 | 2013-02-22 |
Angioedema (3) · Angioedemas, Hereditary (3) · Genetic Diseases, Inborn (2) · Activated PI3K-delta Syndrome (1) · Immunologic Deficiency Syndromes (1) · Lymphadenopathy (1)
leniolisib (4) · Sodium Chloride (3) · Complement C1 Inhibitor Protein (2) · conestat alfa (2)
Netherlands (4) · United States (4) · Japan (3) · Italy (2) · Romania (2) · Belarus (1) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · North Macedonia (1) · Poland (1)
Jan Nuijens, MD, PhD (2) · Anurag Relan, MD (1) · Hirokazu Kanegane, Prof. (1)
PMID 42159953, PMID 20920772, PMID 28284978, PMID 22909164, PMID 23535096, PMID 37797893, PMID 38593221
2016 (1)